KR101533910B1 - Composition for preventing and improving hyperlipidemia comprising extracts of Momordica charantia, Corni fructus, Schizandra chinensis and Jujube - Google Patents
Composition for preventing and improving hyperlipidemia comprising extracts of Momordica charantia, Corni fructus, Schizandra chinensis and Jujube Download PDFInfo
- Publication number
- KR101533910B1 KR101533910B1 KR1020140012220A KR20140012220A KR101533910B1 KR 101533910 B1 KR101533910 B1 KR 101533910B1 KR 1020140012220 A KR1020140012220 A KR 1020140012220A KR 20140012220 A KR20140012220 A KR 20140012220A KR 101533910 B1 KR101533910 B1 KR 101533910B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- weight
- jujube
- hyperlipidemia
- cholesterol
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 164
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 244000302512 Momordica charantia Species 0.000 title abstract description 6
- 235000009811 Momordica charantia Nutrition 0.000 title abstract description 6
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 title abstract description 4
- 244000126002 Ziziphus vulgaris Species 0.000 title 1
- 235000013305 food Nutrition 0.000 claims abstract description 44
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 238000000605 extraction Methods 0.000 claims abstract description 13
- 239000002904 solvent Substances 0.000 claims abstract description 10
- 150000005846 sugar alcohols Polymers 0.000 claims abstract description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940043375 1,5-pentanediol Drugs 0.000 claims abstract description 6
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims abstract description 6
- 241001400472 Omiza Species 0.000 claims description 16
- 239000002285 corn oil Substances 0.000 claims description 15
- 235000005687 corn oil Nutrition 0.000 claims description 15
- 235000013361 beverage Nutrition 0.000 claims description 14
- 235000013376 functional food Nutrition 0.000 claims description 14
- 230000036541 health Effects 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 150000001298 alcohols Chemical class 0.000 claims description 7
- 229940041514 candida albicans extract Drugs 0.000 claims description 7
- 239000012138 yeast extract Substances 0.000 claims description 7
- 240000008866 Ziziphus nummularia Species 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 60
- 235000012000 cholesterol Nutrition 0.000 abstract description 26
- 108010023302 HDL Cholesterol Proteins 0.000 abstract description 16
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 10
- 238000002156 mixing Methods 0.000 abstract description 7
- 230000003247 decreasing effect Effects 0.000 abstract description 3
- 240000003584 Ziziphus jujuba Species 0.000 abstract 2
- 235000008529 Ziziphus vulgaris Nutrition 0.000 abstract 2
- 241001247821 Ziziphus Species 0.000 description 41
- 238000002474 experimental method Methods 0.000 description 22
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 21
- 230000000694 effects Effects 0.000 description 15
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 235000005911 diet Nutrition 0.000 description 14
- 230000003078 antioxidant effect Effects 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 11
- 201000005577 familial hyperlipidemia Diseases 0.000 description 11
- 235000012054 meals Nutrition 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 230000037213 diet Effects 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 230000002292 Radical scavenging effect Effects 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 235000013824 polyphenols Nutrition 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 235000013399 edible fruits Nutrition 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 150000008442 polyphenolic compounds Chemical class 0.000 description 7
- 238000008214 LDL Cholesterol Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003925 fat Substances 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 108010028554 LDL Cholesterol Proteins 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000000378 dietary effect Effects 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- -1 serotonins Chemical class 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 238000010241 blood sampling Methods 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 235000013311 vegetables Nutrition 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 240000007124 Brassica oleracea Species 0.000 description 2
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 2
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 2
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 2
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- LNMAXKMUGYXKPJ-UHFFFAOYSA-L calcium;1,1-dioxo-1,2-benzothiazol-2-id-3-one Chemical compound [Ca+2].C1=CC=C2C([O-])=NS(=O)(=O)C2=C1.C1=CC=C2C([O-])=NS(=O)(=O)C2=C1 LNMAXKMUGYXKPJ-UHFFFAOYSA-L 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000019264 food flavour enhancer Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 235000021109 kimchi Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000003176 neuroleptic agent Substances 0.000 description 2
- 230000000701 neuroleptic effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241001454694 Clupeiformes Species 0.000 description 1
- 229920002911 Colestipol Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000209020 Cornus Species 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000251511 Holothuroidea Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 244000167230 Lonicera japonica Species 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 241000673686 Viburnum japonicum Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 1
- 229960005164 acesulfame Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019513 anchovy Nutrition 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229930185803 charantin Natural products 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229940108924 conjugated linoleic acid Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 description 1
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical compound C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- SQYPHCMLIZHTPW-LWIDLGQCSA-N momordicin-28 Chemical compound C([C@@]12C)CC(=O)C(C)(C)[C@@H]1CC[C@]1(C)[C@@H]2C=C[C@]2(O)[C@@H]3[C@@H](C)[C@H](C)CC[C@]3(COC)CC[C@]21C SQYPHCMLIZHTPW-LWIDLGQCSA-N 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000021049 nutrient content Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000028503 regulation of lipid metabolic process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000014438 salad dressings Nutrition 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- BAQAVOSOZGMPRM-UHFFFAOYSA-N sucralose Chemical compound OC1C(O)C(Cl)C(CO)OC1OC1(CCl)C(O)C(O)C(CCl)O1 BAQAVOSOZGMPRM-UHFFFAOYSA-N 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Abstract
Description
본 발명은 여주, 산수유, 오미자 및 대추의 혼합 추출물을 함유한 고지혈증 예방 및 개선용 조성물에 관한 것으로서, 더욱 상세하게는 여주, 산수유, 오미자 및 대추의 혼합 추출물을 이용하여 총콜레스테롤과 중성지방은 낮추고 HDL-콜레스테롤은 증가시켜 고지혈증을 예방하고 개선시킬 수 있는 약학 및 식품 조성물에 관한 것이다. The present invention relates to a composition for preventing and improving hyperlipidemia, which contains a mixed extract of Yeoju, Sansui, Omija and Jujube. More particularly, the present invention relates to a composition for prevention and improvement of hyperlipidemia, comprising total extracts of Yeoju, HDL-cholesterol is increased to prevent and ameliorate hyperlipidemia.
고지혈증(hyperlipidemia)은 고혈압, 당뇨와 함께 국민건강을 위협하는 3대 만성질환으로 자리 잡았다. 건강보험심사평가원이 집계한 고지혈증 환자 통계에 따르면 2008년 74만 명이던 환자 수가 4년 후 122만 명으로 65%가량 크게 증가하였다. 2010년 처음으로 100만 명을 넘어선 고지혈증 환자 수는 서구화된 식생활 등의 여파로 연령대를 가리지 않고 매년 가파른 상승세를 보이고 있다.Hyperlipidemia has become a major chronic disease with high blood pressure and diabetes. According to the statistics of hyperlipidemia patients collected by the Health Insurance Review and Assessment Service, the number of patients increased from 744,000 in 2008 to 1223,000 in 4 years, up by 65%. The number of hyperlipidemia patients, which exceeded one million for the first time in 2010, has risen steadily every year, regardless of age, due to westernized dietary habits.
고지혈증은 혈장 내의 콜레스테롤(cholesterol)과 중성지방(triglycerides)치가 정상보다 높은 경우의 상태를 말한다. 고지혈증, 특히 고콜레스테롤 혈증은 동맥 혈전증을 유발하여 혈관벽에 지질이 두껍게 싸여 동맥경화증을 유발시고, 이는 혈류를 감소시켜 허혈성 심장질환과 협심증, 심근경색, 뇌경색과 같은 혈액순환질환을 초래하므로 초기에 치료하고, 그로 인한 합병증을 예방하는 것이 중요하다.Hyperlipidemia refers to a condition in which the levels of cholesterol and triglycerides in plasma are higher than normal. Hypercholesterolemia, especially hypercholesterolemia, causes arterial thrombosis and causes thickening of the lipid wall in the blood vessel walls to cause atherosclerosis, which causes blood circulation such as ischemic heart disease, angina pectoris, myocardial infarction and cerebral infarction, It is important to prevent complications.
고지혈증에는 다양한 원인들이 있지만 음식으로부터 과다 섭취된 콜레스테롤은 세포 필요량을 만족시키면 남게 되어 혈류를 따라 이동하면서 고지혈증을 야기 시키며, 단핵세포, 거핵세포 등과 함께 혈관 내막에 흡착되어 거품세포로 전환되는 원인이 되고, 이는 결국 동맥 내의 벽을 두껍게 하여 혈류를 차단시킴으로써 협심증, 동맥경화 또는 심장마비 등을 유발하게 된다(Chung et al., 2012. Nutr. Res. 32, 365-373).There are various causes of hyperlipidemia, but hyperlipidemic cholesterol from the food is left when it meets the cell requirement, causing hyperlipidemia while moving along the bloodstream, causing it to be converted into bubble cells with mononuclear cells and megakaryocytes , Which ultimately leads to angina, atherosclerosis or heart attack by blocking the blood flow by thickening the wall in the artery (Chung et al., 2012. Nutr Res. 32, 365-373).
콜레스테롤은 주로 간에서 생성되고 혈액 중에 지단백(lipoprotein) 형태로 존재를 하는데 지단백질 중 고밀도지단백질(high density lipoprotein, HDL)은 다른 조직에서 간으로 콜레스테롤을 운반하기 때문에 HDL-콜레스테롤이 많으면 혈관 등에서 콜레스테롤이 제거되며, 반면 저밀도지단백질(low density lipoprotein, LDL)은 간에서 주로 생성되어 인체의 다른 조직으로 콜레스테롤을 운반하므로 LDL-콜레스테롤이 많으면 혈관에 콜레스테롤이 많이 쌓여서 동맥경화가 촉진되며, 혈중 콜레스테롤의 약 70%는 LDL-콜레스테롤 형태로 존재한다. Cholesterol is mainly produced in the liver and is present in the form of lipoprotein in the blood. High density lipoprotein (HDL) among lipoproteins transports cholesterol from liver to liver in other tissues. Therefore, cholesterol is removed from blood vessels and the like when a lot of HDL- In contrast, low density lipoprotein (LDL) is mainly produced in the liver and transports cholesterol to other tissues of the human body. Therefore, when LDL-cholesterol is high, a large amount of cholesterol accumulates in the blood vessels and promotes atherosclerosis. Is present in the form of LDL-cholesterol.
고지혈증을 예방 및 치료를 위해 식사요법, 생활요법 및 약물요법이 사용되고 있고, 가장 일반적인 치료법은 식이요법, 운동요법과 동시에 각종 기능성 식품을 섭취하거나 고지혈증 치료제를 복용하는 것이다. 따라서 고지혈증 예방 및 개선을 위한 각종 기능성 식품 및 신약 개발을 위한 연구들이 활발하게 진행되고 있다.Diet, lifestyle and drug therapy are used for prevention and treatment of hyperlipidemia. The most common treatment methods are dietary and exercise therapy as well as taking various functional food or taking a therapeutic agent for hyperlipemia. Therefore, studies for the development of various functional foods and new drugs for the prevention and improvement of hyperlipemia are being actively carried out.
현재까지 개발된 고지혈증 치료제를 살펴보면 LDL-콜레스테롤을 혈중에서 20-35%까지 낮출 수 있는 콜레스티라민(cholestyramine)과 콜레스티폴(cholestipol)가 있고, 스타틴(HMG-CoA Reductase 억제제)계 약물은 콜레스테롤 합성의 주요 단계인 HMG-CoA에서 메발론산으로 전환시키는 단계를 억제해 간세포 내의 콜레스테롤 양을 줄이고, 그 결과 간세포 표면에 LDL수용체가 증가되어 혈중 LDL 콜레스테롤이 18-55%, 중성지방도 7-30% 감소하며 HDL 콜레스테롤은 5-15% 증가시킨다. 스타틴계 약물들은 로바스타틴(lovastatin), 심바스타틴(simvastatin) 등이 개발되어 시중에 판매되고 있다. Cholestyramine and cholestipol, which can lower LDL-cholesterol to 20-35% in the blood, and statin (HMG-CoA Reductase inhibitor) drugs are cholesterol The major step in the synthesis of HMG-CoA to mevalonic acid is inhibited to reduce the amount of cholesterol in the hepatocyte, resulting in increased LDL receptors on the surface of hepatocytes, resulting in 18-55% of blood LDL cholesterol, 7-30% And increases HDL cholesterol by 5-15%. Statins such as lovastatin and simvastatin have been developed and marketed.
하지만 기존의 약물 복용으로 혈중 콜레스테롤 수치가 정상 수준으로 돌아왔다 해도 약물 복용을 중단하면 혈중 콜레스테롤치가 다시 원상 복귀되거나 오히려 상승할 수 있다. 그리고 장기간 이들 약물을 복용하면 심각한 부작용을 수반하는 경우가 많아 부작용이 적은 천연물에서 고지혈증 치료물질을 찾고자 하는 연구들이 계속되고 있다. However, even if the blood cholesterol level returned to normal level by taking the drug, if you stop taking the drug, your blood cholesterol level may return to normal or may rise. And long-term use of these drugs is often accompanied by serious side effects, so there are few studies on finding substances for treating hyperlipidemia in natural products with fewer side effects.
그리고 고지혈증 초기치료 및 그로 인한 합병증은 예방이 가장 중요하므로 식사요법과 함께 예부터 섭취해 오고 있는 소재를 이용하여 일상적으로 섭취할 수 있는 음료를 발명하여 고지혈증 예방이 가능하므로 고지혈증으로부터 건강을 지키는 가장 현명한 선택이 될 것이다. 또한 식사나 예부터 식용으로 사용되고 있는 소재를 이용하여 발명한 음료 섭취는 부작용이나 약물에 대한 내성이 생길 확률도 최소화할 수 있을 것이다. In addition, since the prevention of hyperlipidemia and early complications are most important, it is possible to prevent the hyperlipemia by inventing beverages that can be ingested daily by using the materials that have been ingested from the past together with the dietary therapy. Therefore, It will be a choice. In addition, the ingestion of beverages, which have been invented using materials used for meals or food for example, may minimize the likelihood of side effects or resistance to drugs.
천연물을 이용한 고지혈증 치료에 대한 연구로서 대한민국 공개 특허 제 2010-0089910호에 상백피, 지골피, 산약, 금은화의 추출물을 이용한 고지혈증 및 당뇨성 고지혈증의 예방 빛 치료용 조성물이 개시되어 있고, 대한민국 공개특허 제 2002-0037452호에 해백과 과루인 등 생약을 이용한 고지혈증 및 협심증 예방 및 치료용 생약조성물이 개시되어 있고, 대한민국 공개특허 제 2004-0027100호에는 대황 추출물을 함유하는 고지혈증 치료제 조성물이 개시되어 있다. As a study on the treatment of hyperlipidemia using natural products, Korean Patent Publication No. 2010-0089910 discloses a composition for preventing and treating hyperlipidemia and diabetic hyperlipidemia using extracts of bovine bark, gingival fibrosis, -0037452 discloses a herbal composition for prevention and treatment of hyperlipidemia and angina using herbal medicine such as sea cucumber and perineum, and Korea Patent Publication No. 2004-0027100 discloses a composition for treating hyperlipidemia, which contains a rhubarb extract.
하지만 아직까지 여주, 산수유, 오미자, 대추의 혼합추출물에 대한 고지혈증 예방 및 개선 효과에 대한 연구나 발명에 대한 보고는 전무하다.However, there have been no studies or inventions on the prevention and improvement of hyperlipidemia of mixed extracts of Yeoju, Sansui, Omija and Jujube.
이에 본 발명자들은 고지혈증 전단계(pre-hyperlipidemia) 성인에게 여주, 산수유, 오미자 그리고 대추의 혼합 추출물을 섭취시켰을 때 혈중 총콜레스테롤과 중성지방을 감소시키고 HDL-콜레스테롤을 증가시킨다는 사실을 확인함으로써 본 발명을 완성하였다. Accordingly, the inventors of the present invention have completed the present invention by confirming that the total cholesterol and triglyceride are decreased and the HDL-cholesterol is increased when the mixed extract of Yeoju, Sansui, Omija and Jujube is fed to an adult pre-hyperlipidemia Respectively.
따라서 본 발명은 천연소재인 여주, 산수유, 오미자 및 대추를 이용하여 인체에 부작용이 없으면서도 고지혈증을 예방하고 개선할 수 있는 약학 및 식품 조성물을 제공하는 데 그 목적이 있다. Accordingly, it is an object of the present invention to provide a pharmaceutical composition and a food composition which can prevent and ameliorate hyperlipidemia without adverse effects on human body by using natural materials such as Yeoju, Sansui, Omija and Jujube.
상기의 목적을 달성하기 위한 본 발명의 일 예에 따른 고지혈증 예방 및 개선용 약학 조성물은, 물, 탄소수 1 내지 4의 저급 알코올, 다가 알코올(부틸렌글리콜, 프로필렌글리콜, 펜틸렌글리콜 중 어느 하나) 또는 이들의 혼합물로부터 선택된 적어도 어느 하나의 추출용매를 가해 추출한 여주 추출물 70 내지 90중량%, 산수유 추출물 5 내지 15중량%, 오미자 추출물 4 내지 10중량%, 대추 추출물 1 내지 5중량%로 혼합된 것을 특징으로 한다.In order to accomplish the above object, the present invention provides a pharmaceutical composition for preventing and / or improving hyperlipidemia comprising water, a lower alcohol having 1 to 4 carbon atoms, a polyhydric alcohol (any one of butylene glycol, propylene glycol, and pentylene glycol) 70 to 90% by weight of a laxative extract obtained by adding and extracting at least one extraction solvent selected from the group consisting of a mixture of Lactococcus aureus and a mixture thereof, 5 to 15% by weight of a corn oil extract, 4 to 10% by weight of an Omija extract and 1 to 5% .
삭제delete
삭제delete
그리고 상기의 목적을 달성하기 위한 본 발명의 다른 예에 따른 고지혈증 예방 및 개선용 식품 조성물은, 물, 탄소수 1 내지 4의 저급 알코올, 다가 알코올(부틸렌글리콜, 프로필렌글리콜, 펜틸렌글리콜 중 어느 하나) 또는 이들의 혼합물로부터 선택된 적어도 어느 하나의 추출용매를 가해 추출한 여주 추출물 70 내지 90중량%, 산수유 추출물 5 내지 15중량%, 오미자 추출물 4 내지 10중량%, 대추 추출물 1 내지 5중량%로 혼합된 것을 특징으로 한다.According to another aspect of the present invention, there is provided a food composition for preventing and improving hyperlipidemia comprising water, a lower alcohol having 1 to 4 carbon atoms, a polyhydric alcohol (any one selected from the group consisting of butylene glycol, propylene glycol and pentylene glycol ) Or a mixture thereof, 70 to 90% by weight of the extract, 5 to 15% by weight of an extract of corn oil, 4 to 10% by weight of an extract of Omija and 1 to 5% by weight of a jujube extract .
삭제delete
삭제delete
상기 식품 조성물은 음료, 과립, 파우더, 환 중에서 선택된 어느 하나의 제형으로 형성된 건강 기능성 식품인 것을 특징으로 한다. Wherein the food composition is a health functional food formed of any one form selected from beverage, granule, powder and ring.
여주, 산수유, 오미자, 대추의 혼합 추출물 섭취는 고지혈증 전단계인 성인에게 총콜레스테롤과 중성지방 수치를 낮추어 주고, HDL-콜레스테롤 수치를 높여 주어 정상 지질 수준으로 회복시킴으로써 고지혈증으로 진행하는 것을 예방하고 고지혈증을 치료 또는 개선할 수 있음을 실험적으로 확인하였다. The intake of mixed extracts of Yeoju, Sansui, Omija, and Jujube decreases the total cholesterol and triglyceride levels in adults who are pre-hyperlipidemic and increases the HDL-cholesterol level to restore normal lipid levels, thereby preventing progression to hyperlipidemia Or improve the performance of the system.
따라서 본 발명은 고지혈증을 예방 및 개선에 유효한 약학 조성물과 식품 조성물을 제공할 수 있으며, 다양한 분야에 기능성 천연 소재로 유용하게 활용할 수 있다.Accordingly, the present invention can provide a pharmaceutical composition and a food composition effective for preventing and improving hyperlipidemia, and can be usefully utilized as a functional natural material in various fields.
또한, 본 발명에서는 고지혈증 개선식사와 함께 여주, 산수유, 오미자, 대추의 혼합 추출물 섭취할 경우 더욱 효과적으로 고지혈증을 예방하거나 개선할 수 있음을 확인하였다. In addition, in the present invention, it was confirmed that when the mixed extract of Yeoju, Sansui, Omija, and Jujube is supplemented with the hyperlipidemia-improving meal, it is possible to more effectively prevent or ameliorate hyperlipemia.
도 1은 고지혈증 개선식사의 식단을 보여주는 사진이고,
도 2는 고지혈증 전단계인 실험대상자가 혼합추출물 섭취시 실험당일(AHLMCSJ 0), 실험시작 후 7일째(AHLMCSJ 7), 실험시작 후 10일째(AHLMCSJ 10), 실험시작 후 15일째(AHLMCSJ 15)의 혈중 총콜레스테롤(total cholesterol) 수치 변화를 나타낸 그래프이고,
도 3은 고지혈증 전단계인 실험대상자가 혼합추출물 섭취시 실험당일(AHLMCSJ 0), 실험시작 후 7일째(AHLMCSJ 7), 실험시작 후 10일째(AHLMCSJ 10), 실험시작 후 15일째(AHLMCSJ 15)의 혈중 HDL-콜레스테롤(high density lipoprotein-cholesterol) 수치 변화를 나타낸 그래프이고,
도 4는 고지혈증 전단계인 실험대상자가 혼합추출물 섭취시 실험당일(AHLMCSJ 0), 실험시작 후 7일째(AHLMCSJ 7), 실험시작 후 10일째(AHLMCSJ 10), 실험시작 후 15일째(AHLMCSJ 15)의 혈중 중성지방(triglyceride) 수치 변화를 나타낸 그래프이다. 1 is a photograph showing the diet of hyperlipidemia-improving meal,
(AHLMCSJ 0), 7 days after the start of the experiment (AHLMCSJ 7), 10 days after the start of the experiment (AHLMCSJ 10) and 15 days after the start of the experiment (AHLMCSJ 15) A graph showing changes in total cholesterol levels in the blood,
(AHLMCSJ 0), 7 days after the start of the experiment (AHLMCSJ 7), 10 days after the start of the experiment (AHLMCSJ 10), and 15 days after the start of the experiment (AHLMCSJ 15) FIG. 2 is a graph showing the change in the high density lipoprotein-cholesterol (HDL)
(AHLMCSJ 0), 7 days after the start of the experiment (AHLMCSJ 7), 10 days after the start of the experiment (AHLMCSJ 10), and 15 days after the start of the experiment (AHLMCSJ 15) This is a graph showing changes in blood triglyceride levels.
이하, 본 발명의 바람직한 실시 예에 따른 고지혈증 예방 및 개선용 조성물에 대하여 구체적으로 설명한다. Hereinafter, a composition for preventing and improving hyperlipemia according to a preferred embodiment of the present invention will be described in detail.
본 발명의 일 실시 예에 따른 고지혈증 예방 및 개선용 조성물은 약학 조성물이다. The composition for preventing and improving hyperlipidemia according to one embodiment of the present invention is a pharmaceutical composition.
본 발명의 고지혈증 예방 및 개선용 약학 조성물은 여주 추출물과 산수유 추출물, 오미자 추출물, 대추 추출물이 혼합된 혼합 추출물을 유효성분으로 함유한다. The pharmaceutical composition for prevention and improvement of hyperlipidemia according to the present invention contains as an active ingredient, a mixed extract of Yeoju extract, Sansori oil extract, Omiza extract and Jujube extract.
여주(Momordica charantia)는 박과(cucurbitaceae)의 덩굴식물의 열매로서, 영어명으로 비터멜론(bitter melon) 이라고도 불린다. 여주의 생리활성 물질로는 식물성 스테롤에 속하는 모몰데신(momordicin), 카란틴(charantin), 공액리 놀레산(conjugated linoleic acid) 등이 알려져 있다(Sathishsekar D and Subramanian S. 2005. Biol. Pharm. Bull. 28, 978-983). 중국, 인도 및 동아시아 등지에서는 여주를 주요한 기능성 채소로 식용하고 있다(Park et al. 2007. Korean J. Medicinal Crop. Sci. 15, 56-61; Ji et al. 2010. J Korean Soc. Food Sci. Nutr. 39, 203-209). Momordica charantia ) is a fruit of the vine plant of cucurbitaceae, also called bitter melon in English name. As a physiologically active substance of Yeoju, momordicin, charantin and conjugated linoleic acid belonging to plant sterols are known (Sathishsekar D and Subramanian S. 2005. Biol. Pharm. Bull 28, 978-983). In the case of China, India, and East Asia, Yeoju is used as a major functional vegetable (Park et al., 2007. Korean J. Medicinal Crop., 15, 56-61, Ji et al. Nutr 39, 203-209).
산수유(Corni fructus)는 층층나무과의 낙엽교목인 산수유나무의 열매로, 익으면 붉은색의 열매가 된다. 예부터 술이나 차 등의 재료로 이용되고 약용으로 쓰이기도 한다(Lee et al. 2012. J Korean Soc. Food Sci. Nutr. 41, 390-395). 산수유는 예로부터 한방에서 다뇨증, 요통, 이명, 폐결핵 치료, 고혈압, 항암, 항균 및 신경쇠약 치료 등의 목적으로 사용되었으며(Seo et al., 1999. Korean J. Postharvest Sci. Technol. 6, 99-103), 항균 및 항산화 작용(Kim, 2005. J. Korean Oil Chemists' Soc. 22, 157-167; Kim et al. 2003. J. Korean Soc. Food Sci. Nutr. 32, 829-832), 항알레르기 효과(Seo et al. 2002. Kor. J. Herbology 17, 1-12) 등의 다양한 효과가 규명되었다. 산수유와 구기자를 이용한 국산 전통차 개발에 관한 연구(Joo, 1998. Korean J. Dietary Culture 3, 377-383), 산수유를 이용한 약주개발(Lee et al. 2008. Korean J. Food Sci. Technol. 40, 1-10) 등에 대해 보고들 등에 알 수 있듯이 산수유는 식생활 속에서 식용되어져 오고 있는 식품 소재이다. Corni fructus ) is a fruit of the seedling tree which is a deciduous tree of the debris tree, and becomes a red fruit when ripe. It is used as a material for alcohol or tea, and it is also used for medicinal use (Lee et al. 2012. J Korean Soc. Food Science Nutr 41, 390-395). It has been used for the purpose of treating polyuria, back pain, tinnitus, pulmonary tuberculosis treatment, hypertension, anticancer, antimicrobial and neuroleptic treatment in oriental herbs (Seo et al., 1999. Korean J. Postharvest Sci. Technol. 32, 829-832), antimicrobial and antioxidant activities (Kim, 2005. J. Korean Oil Chemists' Soc. 22, 157-167, Kim et al., 2003. J. Korean Soc. Food Sci. Allergic effects (Seo et al. 2002. Kor J. Herbology 17, 1-12). A study on the development of Korean traditional tea using corn oil and gugija (Joo, 1998. Korean J. Dietary Culture 3, 377-383), Development of Yakju using corn oil (Lee et al 2008. Korean J. Food Sci. 1-10), etc. As can be seen, corn oil is a food material that has been edible in the diet.
오미자(Schizandra chinensis Baillon)는 목련과 식물의 열매로서 한약재료, 차, 하절기의 화채재료 등 식품원료로 또는 그 색소를 이용한 녹말다식과 오미자주로 가공, 이용되고 있다. 오미자에는 다량의 유기산과 안토시아닌(anthocyanin) 색소가 함유되어 있고(Kim et al. 1973. Korean J. Food Sci. Technol. 5, 178-182), 노화 억제 활성(Nishiyama et al. 1996. Biol. Pharm. Bull. 19, 388-393), 면역조절 작용 및 항균활성(Li et al. 1990. Fee Radic. Biol. Med. 9, 99-104) 등이 알려져 있다. 더하여 오미자를 이용한 식초제조에 대한 연구보고(Lim and Sul. 2004. J. East Asian Soc. Dietary Life 14, 508-512; Mo et al. 2013. J Korean Soc. Food Sci. Nutr. 42, 441-449)도 알려져 있다. 이들 보고들에서 알 수 있듯이 오미자는 예부터 다양한 목적으로 활용 가능한 식재료로 활용되고 있다. Schizandra chinensis Baillon) is a fruit of magnolia and plant. It is used as a raw material for food such as herbal medicine materials, tea, and green lacquer materials in the summer season, or starch desserts and omija using these pigments. It has been reported that omega contains a large amount of organic acids and anthocyanin pigments (Kim et al. 1973. Korean J. Food Sci. Technol 5, 178-182), aging inhibitory activity (Nishiyama et al. Bull., 19, 388-393), immunomodulatory and antimicrobial activities (Li et al., 1990. Fee Radic. In addition, a study on the production of vinegar using Omija (Lim and Sul. 2004. J. East Asian Soc. Dietary Life 14, 508-512; Mo et al. 2013. J Korean Soc. Food Sci. 449). As can be seen from these reports, omija has been used as a foodstuff for various purposes.
대추(Zizyphus jujuba)는 갈매나무과(Rhamnace)의 지지푸스(Zizyphus)속 낙엽활엽교목의 열매로 북아프리카와 서유럽의 원산지이다. 대추의 영어명으로 Jujube라 불리며, 약용성분으로는 각종 스테롤, 알칼로이드, 사포닌, 비타민, 세로토닌(serotonin), 유기산, 지방산류, 폴리페놀, 히드록시메틸푸프푸랄, 플라보노이드 및 아미노산류 등이 보고되어 있다(Zryaev et al. 1977. Khim. Prir. Soedin. USSR. 2, 239-243; Okamura et al. 1981. Chem. Pharm. Bull. Japan. 29, 675-683). 대추는 예로부터 건강식품으로서 영양성분이 풍부하며 한약재로 사용하고 있으며, 대추는 강장작용(Na et al. 1996. J. Korean Soc. Food Sci. Nutr. 25, 839-845), 항암(Choi et al. 2003. J. Resource Development 22, 23-29), 항염증(Al-Reza et al. 2010. Food Chem. Toxicol. 48, 639-643), 결핵, 기관지염 및 신경쇠약 치료효과(Lee and Cho, 1995. J. Korean Soc. Food Nutr. 24, 127-132) 등의 효능이 있다는 것으로 알려져 있다. 대추는 과용으로 섭취하여도 부작용이 없고 건강 기능성 물질이 다량 함유되어 있어 약선식품으로 이용되고 있다(Kim et al. 2013. J. Korean Soc. Food Sci. Nutr. 42, 1242-1248).Jujube ( Zizyphus) jujuba ) is a deciduous broad-leaved arboreous tree of the genus Zizyphus (Rhamnace). It is the origin of North Africa and Western Europe. It has been reported that jujube is an English name of jujube and various sterols, alkaloids, saponins, vitamins, serotonins, organic acids, fatty acids, polyphenols, hydroxymethylpuffural, flavonoids and amino acids are reported as medicinal ingredients (Zryaev et al, 1977. Khim, Prir, Soedin, USSR, 2, 239-243, Okamura et al., 1981. Chem. Pharm. Bull., 29, 675-683). Jujube has long been used as a health food and has been used as a medicinal herb, and jujube has been used as a medicinal product (Na et al. 1996. J. Korean Soc. Food Sci. Nutr. 25, 839-845) Al and Reza et al 2010. Food Chem. Toxicol 48, 639-643), tuberculosis, bronchitis and neuroleptic treatment effects (Lee and Cho 2003. J. Resource Development 22, 23-29) , 1995. J. Korean Soc. Food Nutr. 24, 127-132). Jujube has been used as an over-the-counter medicinal product because it has no adverse effects even when overdosed and contains a large amount of health functional substances (Kim et al., 2013, J. Food Sci., Nutr 42, 1242-1248).
이와 같이 본 발명에 사용한 여주, 산수유, 오미자 그리고 대추는 예부터 식용으로 사용하고 있는 식재료이므로 장기간 섭취에도 부작용이 없고 환자의 내성을 유발하지 않는 천연 소재이다. As described above, Yeoju, Sansui oil, Omija, and Jujube used in the present invention are natural ingredients that do not cause side effects and tolerance to patients even for long-term ingestion because they are used as foods for a long time.
본 발명은 여주, 산수유, 오미자, 대추가 갖는 각각의 효과가 더해져 고지혈증 예방 및 개선에 더욱 향상된 효과를 가질 수 있도록 여주 추출물, 산수유 추출물, 오미자 추출물, 대추 추출물이 혼합된 혼합추출물을 이용한다. The present invention uses mixed extracts of Yeoju extract, Sansui oil extract, Omiza extract and Jujube extract so that each effect of Yeoju, Sansui oil, Omija and Jujube will be further enhanced to prevent and improve hyperlipidemia.
혼합추출물의 일 예로 여주 추출물 70 내지 90중량%, 산수유 추출물 5 내지 15중량%, 오미자 추출물 4 내지 10중량%, 대추 추출물 1 내지 5중량%로 혼합하여 조성한다. 상기 범위 내에서 여주 추출물, 산수유 추출물, 오미자 추출물, 대추 추출물의 혼합은 우수한 고지혈증 예방 및 개선 효과를 가질 수 있다. An example of the mixed extract is a mixture of 70% to 90% by weight of the extract, 5% to 15% by weight of the extract of corn oil, 4% to 10% by weight of the extract, and 1% to 5% by weight of the jujube extract. Within the above range, the mixing of the extract of L. japonica, the extract of Cornus sylvestris, the extract of Omiza, and the jujube extract may have an excellent effect of preventing and improving hyperlipidemia.
추출물은 다양한 방법으로 추출이 가능하다. 가령, 여주 추출물을 얻기 위해 여주에 추출용매를 가하여 열수추출, 냉침 또는 온침 추출할 수 있다. 이 경우 여주에 대하여 추출용매를 중량비로 2 내지 20배를 가하여 혼합한 후 10 내지 150℃에서 1 내지 24시간 동안 추출한다. 여기서 추출용매로 물, 탄소수 1 내지 4의 저급 알코올, 다가 알코올 또는 이들의 혼합물로부터 선택된 적어도 어느 하나를 이용할 수 있다. 탄소수 1 내지 4의 저급 알코올로 메탄올, 에탄올 등을 이용할 수 있고, 다가 알코올로 부틸렌글리콜, 프로필렌글리콜, 펜틸렌글리콜 등을 이용할 수 있다. 그리고 혼합물로는 물 및 저급 알코올의 혼합물, 물 및 다가 알코올의 혼합물, 저급 알코올 및 다가 알코올의 혼합물, 또는 물 및 저급알코올 및 다가 알코올의 혼합물을 이용할 수 있다. Extracts can be extracted in a variety of ways. For example, in order to obtain an extract of Yeoju, an extraction solvent may be added to the Yeoju to extract hot water, cold-water or warm-up extract. In this case, the extractant is mixed with the extraction solvent at a weight ratio of 2 to 20 times, and the mixture is extracted at 10 to 150 ° C for 1 to 24 hours. The extraction solvent may be at least one selected from water, lower alcohols having 1 to 4 carbon atoms, polyhydric alcohols, and mixtures thereof. As the lower alcohol having 1 to 4 carbon atoms, methanol, ethanol and the like can be used. As the polyhydric alcohol, butylene glycol, propylene glycol, pentylene glycol and the like can be used. Mixtures of water and lower alcohols, mixtures of water and polyhydric alcohols, mixtures of lower alcohols and polyhydric alcohols, or mixtures of water and lower alcohols and polyhydric alcohols can be used as the mixture.
또한, 추출물은 환류냉각추출, 초음파 추출방법, 초임계 유체 추출방법 등을 이용하여 수득할 수 있다. 또한, 상술한 추출방법뿐만 아니라, 통상적인 정제 과정을 거친 추출물도 포함한다. 예컨대, 일정한 분자량 컷-오프 값을 갖는 한외여과막을 이용한 분리, 다양한 크로마토그래피에 의한 분리 등, 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 활성 분획도 추출물에 포함되는 것이다.In addition, the extract can be obtained by using reflux cooling extraction, ultrasonic extraction, supercritical fluid extraction, or the like. In addition to the above-described extraction method, an extract obtained through a conventional purification process is also included. For example, an active fraction obtained through various purification methods, such as separation using an ultrafiltration membrane having a constant molecular weight cut-off value, separation by various chromatographies, etc., is also included in the extract.
산수유 추출물, 오미자 추출물, 대추 추출물 역시 상술한 여주 추출물의 추출방법과 동일하게 추출할 수 있다. The extract of corn oil, Omiza extract, and jujube extract can be extracted in the same manner as described above.
상술한 혼합추출물은 여주 추출물, 산수유 추출물, 오미자 추출물, 대추 추출물을 각각 추출한 후 일정 비율로 혼합한 것을 예로 들었지만 이와 달리 여주, 산수유, 오미자, 대추를 일정 비율로 혼합한 상태에서 추출용매를 가해 추출할 수 있음은 물론이다. 가령, 여주 70 내지 90중량%, 산수유 5 내지 15중량%, 오미자 4 내지 10중량%, 대추 1 내지 5중량%로 혼합한 혼합물에 추출용매를 가하여 열수추출, 냉침 또는 온침 추출할 수 있다. 이 경우 혼합물에 대하여 추출용매를 중량비로 2 내지 20배를 가하여 혼합한 후 10 내지 150℃에서 1 내지 24시간 동안 추출하여 혼합추출물을 수득할 수 있다. 추출용매와 추출방법은 상술한 바와 동일하다. The above-mentioned mixed extracts were obtained by extracting Yeoju extract, Corn oil extract, Omiza extract and Jujube extract and mixing them at a certain ratio. However, in case of mixing Yeoju, Sansui, Omija and Jujube at a certain ratio, Of course. For example, an extraction solvent may be added to a mixture of 70 to 90% by weight of flax, 5 to 15% by weight of marine oil, 4 to 10% by weight of omija and 1 to 5% by weight of jujube, and the mixture may be subjected to hot water extraction, In this case, the mixture may be mixed with the extraction solvent at a weight ratio of 2 to 20 times, and the mixture may be extracted at 10 to 150 ° C for 1 to 24 hours to obtain a mixed extract. The extraction solvent and extraction method are the same as described above.
본 발명의 고지혈증 예방 및 개선용 약학 조성물은 가축, 인간 등을 포함하는 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내(intracerebroventricular) 주사에 의해 투여될 수 있다. The pharmaceutical composition for preventing and ameliorating hyperlipemia of the present invention can be administered to mammals including livestock, human and the like by various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine or intracerebroventricular injections.
본 발명의 약학 조성물은 혼합 추출물에 약학적으로 허용가능한 적절한 담체, 부형제 및 희석제 등을 첨가하여 산제, 과립제, 정제, 캡슐제, 현탁제, 유화제, 시럽제와 같은 경구제제, 주사제, 흡입제, 좌제, 패취제 등의 형태로 제형화하여 사용할 수 있음은 물론이다. 이 경우 약학 조성물 총 중량에 대하여 혼합 추출물을 0.01 내지 99중량% 함유할 수 있다. 바람직하게 0.05 내지 50중량%이다. The pharmaceutical composition of the present invention may be prepared by adding appropriate pharmaceutically acceptable carriers, excipients, diluents and the like to the mixed extract to prepare oral preparations such as powders, granules, tablets, capsules, suspensions, emulsions and syrups, injections, inhalants, It can be used in the form of a patch or the like. In this case, the mixed extract may be contained in an amount of 0.01 to 99% by weight based on the total weight of the pharmaceutical composition. Preferably 0.05 to 50% by weight.
경구 투여용으로 제조하는 경우, 예를 들어 결합제(예: 예비 젤라틴화된 옥수수 전분, 폴리비닐피롤리돈, 하이드록시프로필 메틸셀루로즈 등); 충전제(예: 락토즈, 미세결정성 셀루로즈, 인산 칼슘 등); 윤활제(예: 마그네슘 스테아레이트, 활석, 실리카 등), 붕해제(예: 감자 전분, 나트륨 전분 글리콜레이트 등); 또는 습윤제(예: 나트륨 라우릴 설페이트 등)와 같은 약제학적으로 허용되는 부형제를 포함하여 제조될 수 있다. 대표적으로는 고체 투여형인 과립제, 산제, 정제, 캡슐제, 등의 형태이며, 정제 또는 캡슐제는 이 기술 분야에 알려진 방법에 의해 코팅될 수 있다.When prepared for oral administration, for example, binders (e.g., pregelatinized corn starch, polyvinylpyrrolidone, hydroxypropylmethylcellulose, etc.); Fillers such as lactose, microcrystalline cellulose, calcium phosphate, and the like; Lubricants such as magnesium stearate, talc, silica, etc., disintegrants such as potato starch, sodium starch glycolate, and the like; Or a pharmaceutically acceptable excipient such as a wetting agent (e.g., sodium lauryl sulfate and the like). Typically, it is in the form of solid dosage forms such as granules, powders, tablets, capsules, etc. Tablets or capsules can be coated by methods known in the art.
경구 투여용 액체 제제는 예를 들어 용액, 시럽, 에멀젼, 또는 현탁액 등의 형태를 취할 수 있고, 사용 전에 물 또는 다른 적절한 비히클과 함께 구성되기 위한 건식 생성물로서 존재할 수 있다.Liquid preparations for oral administration may take the form of, for example, solutions, syrups, emulsions, or suspensions, and may be presented as a dry product for constitution with water or other suitable vehicle before use.
이러한 액체 제제는, 임의로 약제학적으로 허용되는 첨가제, 예를 들어 현탁화제(예: 소르비톨 시럽, 메틸셀루로즈, 하이드록시-프로필 메틸셀루로즈, 수소화 식용성 지방 등); 유화제(예: 레시틴, 아라비아 검 등); 비수성 비히클(예: 알몬드 오일, 오일성 에스테르, 에틸 알콜 등); 방부제(예: 메틸 또는 프로필 p-하이드록시벤조에이트, 소르브산 등)를 추가적으로 포함할 수 있으며 통상적인 방법에 의해 제조될 수 있다. 약제학적으로 허용되는 감미료는 바람직하게는 적어도 하나의 감미료, 예를 들어 사카린, 소디움 사카린, 칼슘 사카린, 아스팔탐, 아세설팜 포타시움, 소디움 사이클라메이트, 알리탐, 디하이드로찰콘 감미료, 모넬린, 스테비오시드 또는 슈크랄로즈(4,1',6'-트리클로로-4,1',6'-트리데옥시갈락토슈크로즈), 임의의 벌크 감미료 (예: 소르비톨, 만니톨, 프럭토즈, 슈크로즈, 말토즈, 이소몰트, 글루코즈, 수소화 글루코즈시럽, 크실리톨, 카라멜 또는 꿀 등), 바람직하게는 사카린, 소디움 사카린, 칼슘 사카린, 및 임의의 벌크 감미료(예: 소르비톨, 만니톨, 프럭토즈 등을 포함할 수 있다. Such liquid preparations may optionally contain pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methylcellulose, hydroxy-propylmethylcellulose, hydrogenated edible fats and the like); Emulsifiers (e.g., lecithin, gum arabic, etc.); Non-aqueous vehicles such as almond oil, oily esters, ethyl alcohol, and the like; Preservatives (e.g., methyl or propyl p-hydroxybenzoate, sorbic acid, etc.), and may be prepared by conventional methods. Pharmaceutically acceptable sweeteners preferably include at least one sweetener such as saccharin, sodium saccharin, calcium saccharin, asphaltene, acesulfame potasium, sodium cicamate, alitam, dihydrochalcone sweetener, monelin, Stevioside or sucralose (4,1 ', 6'-trichloro-4,1', 6'-trideoxygalactosucrose), any bulk sweetener such as sorbitol, mannitol, fructose, Such as sucrose, sodium saccharin, calcium saccharin, and any bulk sweetener such as sorbitol, mannitol, fructose, and the like, such as sucrose, glucose, hydrogenated glucose syrup, xylitol, caramel or honey, . ≪ / RTI >
비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
본 발명의 약학 조성물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 가령, 1일 0.0001 내지 100mg/kg으로, 바람직하게는 0.001 내지 10 mg/kg으로 투여될 수 있다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다.The preferred dosage of the pharmaceutical composition of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the drug form, the administration route and the period, but can be appropriately selected by those skilled in the art. For example, 0.0001 to 100 mg / kg, preferably 0.001 to 10 mg / kg per day. The administration may be carried out once a day or divided into several times.
한편, 본 발명의 다른 실시 예는 여주, 산수유, 오미자, 대추가 혼합된 혼합물로부터 추출한 혼합 추출물을 유효성분으로 함유하여 고지혈증 예방 및 개선 효과를 갖는 식품 조성물이다. Meanwhile, another embodiment of the present invention is a food composition having an effect of preventing and improving hyperlipidemia, comprising a mixed extract extracted from a mixture of Yeoju, Sansui, Omija and Jujube as an active ingredient.
혼합 추출물의 양은 전체 식품 조성물 중량의 0.1 내지 90중량%로 함유될 수 있으며, 건강 및 위생을 목적으로 하거나 건강 조절을 목적으로 하는 장기간 섭취의 경우에는 상기 범위 이하일 수 있으며, 혼합 추출물은 안전성 면에서 아무런 문제가 없기 때문에 상기 범위 이상의 양으로 사용될 수 있으므로 상기 범위에 한정되는 것은 아니다.The amount of the mixed extract may be 0.1 to 90% by weight of the total food composition, and may be less than the above range for health and hygiene purposes or long-term intake for health control purposes. It is not limited to the above range since it can be used in an amount of more than the above range because there is no problem.
상기에서 '식품 조성물'이란, 영양소를 한 가지 또는 그 이상 함유하고 있는 천연물 또는 가공품을 의미하며, 바람직하게는 어느 정도의 가공 공정을 거쳐 직접 먹을 수 있는 상태가 된 것을 의미하며, 통상적인 의미로서, 식품, 식품 첨가제, 기능성 식품 및 음료를 모두 포함하는 것을 말한다.The term "food composition" as used herein means a natural product or a processed product containing one or more nutrients. Preferably, the food composition is in a state in which it can be directly eaten through a certain processing step. , Food, food additives, functional foods and beverages.
본 발명에 따른 식품으로는 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 기능성 식품 등이 있다. 추가로, 식품은 특수영양식품(예, 조제유류, 영,유아식 등), 식육가공품, 어육제품, 두부류, 묵류, 면류(예, 라면류, 국수류 등), 빵류, 건강보조식품, 조미식품(예, 간장, 된장, 고추장, 혼합장 등), 소스류, 과자류(예, 스넥류), 캔디류, 쵸코렛류, 껌류, 아이스크림류, 유가공품(예, 발효유, 치즈 등), 기타 가공식품, 김치, 절임식품(각종 김치류, 장아찌 등), 음료(예, 과실 음료, 채소류 음료, 두유류, 발효음료류 등), 천연조미료(예, 라면 스프 등)를 포함하나 이에 한정되지 않는다. 상기 식품은 통상의 제조방법으로 제조될 수 있다.Foods according to the present invention include, for example, various foods, beverages, gums, tea, vitamin complexes, and functional foods. In addition, the food may be selected from the group consisting of special nutritional foods (eg crude oil, milk, baby food, etc.), meat products, fish products, tofu, jelly, noodles (Eg soy sauce), candy, chocolate, gum, ice cream, dairy products (eg fermented milk, cheese, etc.), other processed foods, kimchi, pickled foods (E.g., various kinds of kimchi, pickles, etc.), beverages (e.g., fruit drinks, vegetable beverages, beverages, fermented beverages, etc.) and natural seasonings (e.g., ramen soup and the like). The food can be prepared by a conventional production method.
나아가 본 발명은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 충진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있으며, 상기 성분은 독립적으로 또는 조합하여 사용할 수 있다.Furthermore, the present invention provides a flavor enhancer and a flavor enhancer which can be suitably used as flavorings such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and fillers (cheese, chocolate etc.), pectic acid and its salts, alginic acid and its salts, Stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages, etc. These components may be used independently or in combination.
바람직하게 식품 조성물은 건강 기능성 식품으로 제공될 수 있다. 여기서 '건강 기능성 식품'이란 식품에 물리적, 생화학적, 생물공학적 수법 등을 이용하여 해당 식품의 기능을 특정 목적에 작용, 발현하도록 부가가치를 부여한 식품군이나 식품 조성이 갖는 생체방어리듬조절, 질병방지와 회복 등에 관한 체내조절기능을 생체에 대하여 충분히 발현하도록 설계하여 가공한 식품을 의미한다. Preferably, the food composition can be provided as a health functional food. Here, "health functional food" refers to a food group that gives added value to the function of the food by using physical, biochemical, biotechnological techniques, etc. to control the function of the food, Means a food which is designed and processed so that the body's control function regarding recovery and the like is sufficiently expressed in living bodies.
상기 건강 기능성 식품에는 식품학적으로 허용 가능한 식품 보조 첨가제를 포함할수 있으며, 기능성 식품의 제조에 통상적으로 사용되는 적절한 담체, 부형제 및 희석제를 더욱 포함할 수 있다.The health functional food may include a food-acceptable food-aid additive, and may further include suitable carriers, excipients and diluents conventionally used in the production of functional foods.
건강 기능성 식품은 다양한 형태로 제형이 가능하므로 그 형태는 특별히 제한되지 않는다. 바람직하게 건강 기능성 식품은 음료, 과립, 파우더, 환 중에서 선택된 어느 하나의 제형으로 형성될 수 있다. 이러한 음료, 과립, 파우더, 환 제형을 갖는 건강 기능성 식품은 휴대가 간편하고 언제 어디서나 수시로 섭취하기가 용이하다. The health functional food can be formulated into various forms, and the form thereof is not particularly limited. Preferably, the health functional food may be formed into any one form selected from beverage, granule, powder, and ring. Healthy functional foods having such beverages, granules, powders, and ring formulations are easy to carry and are easily ingested at any time and anywhere.
건강 기능성 식품의 제형의 일 예로, 음료는 혼합 추출물 1 내지 80중량%, 정제수 20 내지 99중량%일 수 있다. 또한, 음료에 첨가물로 타우린, 구연산, 비타민C, 탄수화물 등을 더 첨가할 수 있다. 상기 탄수화물은 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등이다. 이외에도 통상의 음료와 같이 여러 가지 향미제가 추가 성분으로서 함유될 수 있다. 향미제로서 타우마틴, 스테비아 추출물 등의 천연 향미제를 사용할 수 있다. As one example of the formulation of the health functional food, the beverage may be 1-80% by weight of the mixed extract and 20-99% by weight of the purified water. Further, taurine, citric acid, vitamin C, carbohydrates and the like may be further added as an additive to beverages. The carbohydrate may be a monosaccharide such as glucose, fructose, etc .; Disaccharides such as maltose, sucrose and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and xylitol, sorbitol, erythritol, and the like. In addition, various flavorings such as ordinary beverages may be contained as additional ingredients. Natural flavoring agents such as tau martin and stevia extract can be used as flavorings.
과립, 파우더, 환 등의 제형은 혼합 추출물 10 내지 80중량%을 함유하고, 기타 점착제, 향미료, 비타민, 탄수화물 등을 더 추가로 함유할 수 있다. The formulations such as granules, powders, and rings contain 10 to 80% by weight of the mixed extract, and may further contain other adhesive, spice, vitamin, carbohydrate and the like.
일 예로, 환은 혼합 추출물 40중량%와, 점착제 50중량%와, 탄수화물 8중량%와, 향미료 2중량%을 혼합하여 반죽한 후 통상의 제환기에서 녹두알 크기의 환을 성형한 다음 열풍건조기에서 건조시켜 제조한다. 상기 점착제로 물엿 또는 꿀, 밀가루 풀을 이용할 수 있다. For example, a mixture of 40% by weight of a ring-mixed extract, 50% by weight of a pressure-sensitive adhesive, 8% by weight of a carbohydrate and 2% by weight of a spice is kneaded and kneaded in a conventional ventilator, And dried. As the pressure-sensitive adhesive, starch syrup, honey, and flour paste may be used.
제환기 대신 과립기를 이용하여 직경 0.5 내지 1.5mm의 과립상으로 성형할 수 있음은 물론이다. 또한, 제조된 과립을 적당량씩 압출 성형하여 정제로 하거나, 캡슐에 충전하여 캡슐 형태로 제조할 수 있다. It is of course possible to form granules having a diameter of 0.5 to 1.5 mm by using a granulator instead of the ventilation. In addition, the granules may be extruded and granulated in an appropriate amount to prepare tablets, or they may be filled into capsules to form capsules.
이하, 본 발명의 이해를 돕기 위하여 실시 예를 제시하나, 하기 실시 예는 본 발명을 예시하는 것일 뿐 본 발명의 범위가 하기 실시 예에 한정되는 것은 아니다.EXAMPLES Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the scope of the present invention is not limited to the following examples.
<혼합 추출물의 선정><Selection of mixed extract>
활성산소종(reactive oxygen species, ROS)은 세포의 노화나 흡연, 비만, 인슐린 저항성 등의 원인에 의해 그 생성속도가 증가되며, 전반적인 세포 독성을 초래하여 노화 현상이나 다양한 질환의 병리 현상을 초래하는 것으로 알려져 있다(Valko, M. et al., Free radicals, metals and antioxidants in oxidative stress-induced cancer. 10, pp.1-40, 2006). 이와 같이 활성산소종에 의한 피해의 90% 이상이 각종 암, 뇌졸중, 동맥경화, 당뇨병, 일반 염증, 파킨슨 병 등 다양한 질병의 원인이 된다. 따라서 여주, 산수유, 오미자, 대추 각각의 추출물과 이들의 혼합 추출물의 항산화활성을 측정하여 이를 토대로 고지혈증의 예방 및 개선에 가장 우수한 추출물을 찾고자 한다. The reactive oxygen species (ROS) is increased by the causes of cell senescence, smoking, obesity, insulin resistance, etc., resulting in overall cytotoxicity, leading to aging and various disease pathologies (Valko, M. et al., Free radicals, metals and antioxidants in oxidative stress-induced cancer. 10, pp. 1-40, 2006). Thus, more than 90% of the damage caused by reactive oxygen species causes various diseases such as various cancers, strokes, arteriosclerosis, diabetes, general inflammation, and Parkinson's disease. Therefore, we aimed to find the best extracts for the prevention and improvement of hyperlipemia based on the antioxidant activity of extracts of Yeoju, Sansui, Omija and Jujube extracts and their mixed extracts.
여주, 산수유, 오미자, 대추 각각에 대하여 물을 중량비로 10배를 가한 후 110℃에서 4시간 동안 열수추출한 후 여과지로 여과하여 여주 추출물, 산수유 추출물, 오미자 추출물, 대추 추출물을 각각 수득하였다. Each of water, milk powder, omija, and jujube was added 10 times by weight of water, followed by hot water extraction at 110 ° C for 4 hours, followed by filtration through a filter paper to obtain Yeast extract, Corn oil extract, Omiza extract and Jujube extract.
여주의 다양한 약리적 효과를 고려하여 여주 추출물을 주재료로 정한 후 산수유 추출물, 오미자 추출물, 대추 추출물 중 어느 하나 이상의 추출물을 첨가하는 방식으로 혼합추출물을 제조하였다. 다양한 혼합과 비율로 제조한 혼합추출물들은 관능검사를 통해 소비자의 기호도를 파악한 다음 기호도가 우수한 아래의 3가지 혼합추출물을 실험에 이용하였다. In order to investigate various pharmacological effects of Yeoju, Yeoju extract was selected as a main ingredient, and then mixed extracts were prepared by adding at least one extract of corn oil extract, Omiza extract and jujube extract. The mixed extracts prepared by various blends and ratios were analyzed by sensory evaluation, and then the following three mixed extracts with favorable taste were used for the experiment.
제 1혼합추출물은 여주 추출물 80중량%, 산수유 추출물 10중량%, 증류수 10중량%를 혼합하여 조성하였고, 제 2혼합추출물은 여주 추출물 80중량%, 산수유 추출물 10중량%, 오미자 추출물 10중량%를 혼합하여 조성하였고, 제 3혼합추출물은 여주 추출물 80중량%, 산수유 추출물 10중량%, 오미자 추출물 7중량%, 대추 추출물 3중량%를 혼합하여 조성하였다. The first mixed extract was prepared by mixing 80% by weight of Yeast extract, 10% by weight of Sansui oil extract and 10% by weight of distilled water, and the second mixed extract contained 80% by weight of Yeast extract, 10% by weight of Sansui oil extract, 10% , And the third mixed extract was prepared by mixing 80% by weight of Yeast Extract, 10% by weight of Sansui Oil Extract, 7% by weight of Omiza Extract, and 3% by weight of Jujube Extract.
여주 추출물, 산수유 추출물, 오미자 추출물, 대추 추출물, 제 1혼합추출물, 제 2혼합추출물, 제 3혼합추출물을 시료로 각각 이용하여 항산화 활성을 실험하였다. The antioxidative activities of the extracts of Yeoju, Sanswort, Omija, Jujube, 1st, 2nd and 3rd mixed extracts were investigated.
각 시료를 미세여과 필터와 여과지(Whatman, No. 2)로 감압 여과하여 고형물질을 제거한 다음 50mL로 농축(Tokyo rkiakikai, N-1000, Japan)하고 증류수를 가해 2mg/mL 농도로 희석하여 사용하였다. Each sample was filtered through a microfiltration filter and a filter paper (Whatman, No. 2) to remove solids, and then concentrated to 50 mL (Tokyo rkiakikai, N-1000, Japan), diluted with distilled water to a concentration of 2 mg / mL .
시료 1.8mL에 1.5×10-4M의 DPPH(1,1-diphenyl-2-picryl hydrazyl) 1.2mL를 교반한 후 37℃에서 30분간 반응시킨 다음 517nm에서 흡광도를 측정하였다. 라디칼소거활성능은 시료 첨가구와 대조구의 흡광도 감소율로 나타내었다. 대조구는 시료 대신에 증류수를 이용하였다. 라디칼 소거 활성능은 다음과 같은 식에 의해 계산하여 하기 표 1에 나타내었다. 1.2 ml of DPPH (1,1-diphenyl-2-picryl hydrazyl) of 1.5 × 10 -4 M was added to 1.8 ml of the sample, reacted at 37 ° C. for 30 minutes, and the absorbance was measured at 517 nm. The radical scavenging activity was expressed by the absorbance reduction rate of the sample and the control. The control group used distilled water instead of the sample. The radical scavenging activity was calculated by the following equation and is shown in Table 1 below.
라디칼소거활성능(%) = (1-시료첨가구의 흡광도/대조구의 흡광도)×100Radical scavenging activity (%) = (1-absorbance of sample added / absorbance of control) × 100
상기 표 1의 결과를 살펴보면, 여주 추출물, 산수유 추출물, 오미자 추출물, 대추 추출물의 라디칼소거활성능은 각각 5.5, 67.1, 42.6 그리고 86.3% 수준으로 나타났다. 각 추출물에서 여주 추출물이 항산화 효과가 가장 낮게 나타났으며, 대추 추출물의 항산화 효과가 가장 높게 나타났다. The results of Table 1 show that the radical scavenging activity of Yeoju extract, Cornus japonica Extract, Omiza extract and Jujube Extract was 5.5, 67.1, 42.6 and 86.3%, respectively. The extracts showed the lowest antioxidative effect and the jujube extract showed the highest antioxidative effect.
제 1혼합추출물의 라디칼소거활성능은 83.9%였고, 제 2혼합추출물의 라디칼소거활성능은 89.6%였다. 그리고 제 3혼합추출물의 라디칼소거활성능은 92.5%였다. 상기의 실험을 통해 3가지의 혼합추출물 중 제 3혼합추출물의 항산화 효과가 가장 우수한 것으로 나타났다. 또한, 여주 추출물, 산수유 추출물, 오미자 추출물, 대추 추출물 각 단독에 비해 혼합추출물들의 항산화 효과가 더 높음을 확인할 수 있었다. 특히, 제 3혼합추출물은 항산화 효과가 가장 낮은 여주 추출물을 80중량% 함유하였음에도 불구하고 각 단독의 추출물이나 제 1 및 제 2혼합추출물에 비해 항산화 효과가 가장 높았다. 이는 4가지 추출물을 혼합하면 시너지 효과에 의해 항산화 활성을 크게 증대시키는 것으로 추정된다. The radical scavenging activity of the first mixed extract was 83.9% and the radical scavenging activity of the second mixed extract was 89.6%. The radical scavenging activity of the third mixed extract was 92.5%. From the above experiment, the antioxidative effect of the third mixed extract was most excellent among the three mixed extracts. In addition, the antioxidative effect of mixed extracts was higher than that of Yeoju extract, Sansori oil extract, Omiza extract and Jujube extract. In particular, the third mixed extract had the highest antioxidative effect compared to the extracts of the respective alone and the first and second mixed extracts, even though the extract contained 80 wt% of the lowest extract. It is presumed that mixing four kinds of extract greatly increases antioxidant activity by synergy effect.
이하에서는 항산화 활성이 가장 우수한 것으로 확인된 제 3혼합추출물을 이용하여 실험을 진행하였다. Hereinafter, the experiment was conducted using the third mixed extract, which was confirmed to have the highest antioxidant activity.
<혼합추출물의 총 폴리페놀 함량 측정><Total polyphenol content of mixed extracts>
여주 추출물 80중량%, 산수유 추출물 10중량%, 오미자 추출물 7중량%, 대추 추출물 3중량%로 조성된 혼합 추출물의 총 폴리페놀 화합물의 함량은 Folin-Denis법(Gutfinger,1958)을 응용하여 측정하였다. The total polyphenol compound content of the mixed extract consisting of 80% by weight of the extract of Yejoo, 10% by weight of the extract of corn oil, 7% by weight of Omiza extract and 3% by weight of the jujube extract was determined by applying the Folin-Denis method (Gutfinger, 1958) .
혼합추출물 5mL에 Foline-Ciocalteau's phenol regent 0.5mL를 첨가하여 혼합한 다음 실온에서 3분간 방치하였다. 그리고 10% Na2CO3 포화용액 1mL를 가하여 혼합하고 실온에서 1시간 반응시킨 후 상등액을 700nm에서 흡광도를 측정하였다. 표준용액은 카페인산(caffeic acid)을 0-100μg/mL의 농도로 제조하여 동일한 방법으로 분석하였으며, 표준 검량곡선으로부터 혼합추출물의 총 폴리페놀 함량을 계산하여 하기 표 2에 나타내었다. 0.5 mL of Foline-Ciocalteau's phenol regent was added to 5 mL of the mixed extract, and the mixture was allowed to stand at room temperature for 3 minutes. Then, 1 mL of a saturated solution of 10% Na 2 CO 3 was added and reacted at room temperature for 1 hour, and the supernatant was measured for absorbance at 700 nm. The standard solutions were prepared by preparing caffeic acid at a concentration of 0-100 μg / mL and analyzed in the same manner. The total polyphenol content of the mixed extracts was calculated from the standard calibration curves and is shown in Table 2 below.
상기 표 2의 결과를 참조하면, 여주 추출물 80중량%, 산수유 추출물 10중량%, 오미자 추출물 7중량%, 대추 추출물 3중량%로 조성된 혼합추출물의 총 폴리페놀 함량은 85.58±3.95mg%로 높게 나타났다. 총 폴리페놀 함량은 항산화력과 높은 양의 상관관계를 가지고 있다(Kim et al. 2010. J. Korean Soc. Food Sci. Nutr. 39, 193-202). 따라서 총 폴리페놀의 측정결과는 혼합추출물의 높은 항산화활성 실험결과와 일치함을 알 수 있다. Referring to the results shown in Table 2, the total polyphenol content of the mixed extract consisting of 80% by weight of Yeast extract, 10% by weight of Sansui oil extract, 7% by weight of Omiza extract and 3% by weight of jujube extract was 85.58 ± 3.95 mg% appear. Total polyphenol content correlated positively with antioxidant activity (Kim et al. 2010. J. Korean Soc. Food Sci., 39, 193-202). Therefore, the results of total polyphenol measurements are consistent with the high antioxidant activity of mixed extracts.
<혼합 추출물의 탁도, pH 그리고 당도 측정><Turbidity, pH and sugar content of mixed extract>
여주 추출물 80중량%, 산수유 추출물 10중량%, 오미자 추출물 7중량%, 대추 추출물 3중량%로 조성된 혼합추출물의 탁도는 660nm에서 흡광도를 측정하였고, pH는 혼합추출물을 여과한 후 pH meter로 상온에서 측정하였다. 당도(°Brix)는 당도계로 측정하였다. 실험결과는 하기 표 3에 나타내었다. The turbidity of the mixed extract consisting of 80% by weight of Yeoju extract, 10% by weight of corn oil extract, 7% by weight of Omiza extract and 3% by weight of jujube extract was measured at 660 nm and the pH was determined by filtering the mixed extract, Respectively. The sugar content (° Brix) was measured with a sugar meter. The experimental results are shown in Table 3 below.
상기 표 3을 참조하면, 혼합 추출물의 탁도는 660nm에서 0.44였고, pH는 4.38로 약산성인 것으로 나타났으며, 당도는 1.8°Birx 였다. Referring to Table 3, the turbidity of the mixed extract was 0.44 at 660 nm, pH was 4.38, and it was found to be slightly acidic, and the sugar content was 1.8 ° Birx.
상기 표 3의 결과를 통해 고지혈증 예방 및 개선용 식품 조성물의 일 예로서 혼합추출물을 함유한 음료의 개발 가능성을 확인할 수 있었다. As a result of the results shown in Table 3, the possibility of developing a beverage containing a mixed extract as an example of a food composition for preventing and improving hyperlipidemia was confirmed.
<혈액 내 지질 영향 실험><Lipid effect test in blood>
현대인의 고지방 식이 섭취는 체지방 축적에 의한 비만과 함께 혈액 내 중성지방(Triglycer)과 총콜레스테롤(Total cholesterol) 및 유해 콜레스테롤로 알려진 LDL-콜레스테롤 함량을 증가시키고, 유익한 콜레스테롤인 HDL-콜레스테롤 함량을 낮춘다. 혈액 LDL-콜레스테롤의 증가는 심장혈관계질환을 일으킬 수 있는 주원인으로 밝혀졌으며 높은 사망률을 초래할 수 있다(S. M. Grundy, Cholesterol and coronary heart disease, JAMA, 256, 2849-2858 (1986)). 체내의 에너지 대사 과정의 이상으로 야기되는 대사성 질환은 지방세포의 분화 및 지질대사의 조절이상으로 야기되는 고지혈증을 불러일으킬 수 있다.Contemporary high-fat diets increase obesity by accumulating body fat, increase triglycerides, total cholesterol, and LDL-cholesterol, known to be harmful cholesterol, and lower the beneficial cholesterol, HDL-cholesterol. Increased blood LDL-cholesterol has been shown to be a major cause of cardiovascular disease and can lead to high mortality (S. M. Grundy, Cholesterol and coronary heart disease, JAMA, 256, 2849-2858 (1986)). Metabolic diseases caused by abnormality of energy metabolism in the body may cause hyperlipemia caused by differentiation of adipocytes and regulation of lipid metabolism.
본 실험에서는 여주 추출물 80중량%, 산수유 추출물 10중량%, 오미자 추출물 7중량%, 대추 추출물 3중량%로 조성된 혼합추출물이 혈액 내 지질에 어떠한 변화를 주는지를 관찰하여 고지혈증의 예방 및 치료 효과를 살펴보고자 한다. In this experiment, the effect of the mixed extract of 80% by weight of Yeoju Extract, 10% by weight of Sansui Extract, 7% by weight of Omiza Extract and 3% by weight of Jujube Extract, Let's look at it.
1. 실험대상1. Subject
고지혈증의 진단방법으로는 공복 혈액검사로 총콜레스테롤, HDL-콜레스테롤 그리고 중성지방 수치를 기준치와 비교하여 판정한다. 총콜레스테롤은 200mg/dL 미만일 때 정상이고 200~239mg/dL이면 고지혈증 전단계(건강에 이상없으나 자기관리 및 예방조치필요단계)이다. 그리고 HDL-콜레스테롤은 60mg/dL 이상일 때 정상이고 40~59mg/dL 일 때는 고지혈증 전단계 그리고 중성지방은 150mg/dL 미만일 때 정상이고 150-199mg/dL 일 때 고지혈증 전단계이다.The diagnosis of hyperlipidemia is made by comparing the total cholesterol, HDL-cholesterol and triglyceride levels with the baseline values by fasting blood test. When total cholesterol is less than 200 mg / dL, it is normal, and when it is 200 to 239 mg / dL, it is pre-hyperlipidemia (no health problem, but self-management and preventive measures). And HDL-cholesterol is normal at over 60 mg / dL, pre-hyperlipidemia at 40 to 59 mg / dL, normal triglyceride at less than 150 mg / dL and pre-hyperlipidemia at 150-199 mg / dL.
실험 대상자는 총콜레스테롤 200~239mg/dL, HDL-콜레스테롤 40~59mg/dL 그리고 중성지방 150~199mg/dL로서 고지혈증 전단계(pre-hyperlipidemia)인 9명의 성인 지원자였다. The subjects were 9 adult applicants with total cholesterol of 200 ~ 239 mg / dL, HDL-cholesterol of 40 ~ 59 mg / dL and triglycerides of 150 ~ 199 mg / dL as pre-hyperlipidemia.
2. 실험방법2. Experimental Method
실험방법의 개략적인 모식도를 하기 표 4에 나타내었다. A schematic diagram of the experimental method is shown in Table 4 below.
실험은 총 15일 동안 수행하였다. 실험기간 동안 매일 아침, 점심, 저녁으로 3번의 식사를 하도록 하였고, 매 식사 후 100mL의 혼합추출물을 섭취하였다. The experiment was carried out for a total of 15 days. During the experiment, three meals were made every morning, lunch and dinner, and 100 mL of mixed extract was taken after each meal.
실험시작 후 10일째까지는 일반식사(실험대상자가 평소에 먹던 식사)를 하도록 하였고, 11일째부터 15일째까지는 아침과 저녁은 일반식사를 그대로 이용하도록 하였고, 점심은 고지혈증 개선식사(표 5와 도 1)를 이용하도록 하였다. From the 11th day to the 15th day, normal meals were used in the morning and evening, and the lunch was used for the improvement of hyperlipemia (Table 5 and Fig. 1 ) Were used.
실험 시작 전과 실험 시작 후 7, 10, 15일째에 실험대상자의 혈액을 채취하였다. 병원 전문가의 지원을 받아 실험대상자의 혈액을 1mL씩 채취하여 즉시 아이스박스에 넣은 후 실험실로 운반하여 원심분리(X3,000rpm, 20min) 후 혈청을 -20℃에 보관하였다. Blood samples were taken before and 7, 10, and 15 days after the experiment. 1 mL of the blood of the subject was immediately taken in the ice box with the help of a hospital specialist, and then transferred to the laboratory, centrifuged (X3,000 rpm, 20 min) and stored at -20 ° C.
고지혈증 개선식사는 정해진 시간(12:00)에 광주대학교 식품영양학과 조리실에서 조리 후 섭취하였다. 고지혈증 개선식사의 식단을 하기 표 5에 정리하였다.The hyperlipidemic diet was taken at the designated time (12:00) after cooking at the Gourmet Office of Gwangju University. The diet of hyperlipidemia-refractory meals is summarized in Table 5 below.
food
Grains group
Vegetable group
Provincial
Milk group
Fruit group
Bean sprouts radish soup
Grilled mackerel
Cabbage salad dressing
상기 표 5의 식단은 식품교환표를 이용하여 작성한 것으로서, 고지혈증개선 식사에 사용된 식품들을 영양소 조성이 비슷한 6가지 식품군, 즉 곡류군, 어육류군, 채소군, 지방군, 우유군, 과일군으로 분류하고, 각 식품군별로 영양소 함량을 나타내는 교환단위를 기재하였다. The diets of Table 5 were prepared using the food exchange table. Foods used in the hyperlipidemia-improving diet were classified into six food groups having similar nutrient composition, namely, cereals group, fish group, vegetable group, fat group, milk group, The exchange units representing the nutrient content for each food group are listed.
곡류군의 기준단위량인 ‘1교환단위(1 exchange)'는 열량 100kcal, 당질 23g 그리고 단백질 2g이다. 따라서 상기 표 5의 고지혈증개선 식사의 곡류군은 2교환단위이므로 현미밥을 섭취하면 열량 200kcal, 당질 46g 그리고 단백질 4g을 섭취한다는 것을 의미한다. The reference unit quantity of cereal group '1 exchange' is caloric value 100kcal, saccharide 23g and protein 2g. Therefore, the cereal group of the hyperlipemia-improving dietary diet shown in Table 5 is 2 exchange units, meaning that when the rice rice is consumed, it consumes 200 kcal of calories, 46 g of saccharides and 4 g of protein.
참고로, 저지방(저) 어육류군 1교환단위는 열량이 50kcal, 단백질 8g, 지방 2g이고, 중지방(중) 어육류군 1교환단위는 열량 75kcal, 단백질 8g, 지방 5g이고, 채소군 1교환단위는 열량 20kcal, 당질 3g, 단백질 2g이고, 지방군 1교환단위는 열량 45kcal, 지방 5g이고, 과일군 1교환단위는 열량 50kcal, 당질 12g이다. For reference, 1 exchange unit of low-fat (low) fish meat group is 50kcal of heat, 8g of protein, 2g of fat, 1 exchange unit of meat in stopper room (medium) is 75kcal of heat, 8g of protein, 5g of fat, Is a calorie of 20kcal, a saccharide of 3g, a protein of 2g. The fat 1 exchange unit is 45kcal of calories and 5g of fat. The exchange unit of fruit group 1 is 50kcal of calories and 12g of saccharide.
3. 혈액 중 총콜레스테롤, HDL-콜레스테롤, 중성지방 측정3. Measurement of total cholesterol, HDL-cholesterol and triglyceride in blood
실험시작 전(AHLMCSJ0), 실험시작 후 7일째(AHLMCSJ7), 10일째(AHLMCSJ10) 그리고 15일째(AHLMCSJ15)에 실험대상자로부터 채취한 혈액 중의 총콜레스테롤, HDL-콜레스테롤, 중성지방을 측정하였다. 혈액 중의 총콜레스테롤, HDL-콜레스테롤, 중성지방의 함량은 상업용으로 조제된 효소키트(아산제약, 대한민국)로 정량하였고, 그 결과를 도 2 내지 도 4에 나타내었다. Total cholesterol, HDL-cholesterol, and triglyceride were measured in the blood from the subjects before the experiment (AHLMCSJ0), 7 days after the start of the experiment (AHLMCSJ7), 10 days (AHLMCSJ10) and 15 days (AHLMCSJ15). The contents of total cholesterol, HDL-cholesterol, and triglyceride in the blood were quantitatively determined as an enzyme kit (Asan Pharmaceutical, Korea) prepared for commercial use, and the results are shown in Figs. 2 to 4.
도 2 내지 도 4를 참조하면, 실험기간 동안 혼합추출물의 섭취기간이 증가할수록 혈중 총콜레스테롤(total cholesterol) 및 중성지방(triglyceride)의 수치는 감소하였고(도 2 및 도 4), HDL-콜레스테롤(HDL-cholesterol) 수치는 증가하였다(도 3). 중성지방과 총콜레스테롤의 증가는 심근경색, 동맥경화증과 같은 심장혈관계 질환의 발병을 높이고, HDL-콜레스테롤의 증가는 이를 예방하는 데 도움이 되는 것으로 알려져 있다(J. Jensen., B. Anette., D. Steen., H. Kjeld, and H. Gunhild, The effect of palm oil, lard and puff-pastry margarine on postprandial lipid and hormone responses in normal-weight and obese young women, Brit. J. Nutr, 82, 469-479 (1999)).Referring to FIGS. 2 to 4, the total cholesterol and triglyceride levels decreased as the intake period of the mixed extracts increased during the experimental period (FIGS. 2 and 4), and HDL-cholesterol HDL-cholesterol) levels increased (FIG. 3). The increase in triglyceride and total cholesterol has been shown to increase the incidence of cardiovascular diseases such as myocardial infarction and atherosclerosis, and the increase in HDL-cholesterol is known to help prevent it (J. Jensen., B. Anette., D. Steen., H. Kjeld, and H. Gunhild, The effect of palm oil, lard and puff-pastry on margarine on postprandial lipid and hormone responses in normal-weight and obese young women, J. Nutr, 82, 469 -479 (1999)).
상기 실험결과를 통해 고지혈증 전단계(pre-hyperlipidemia)에 있는 실험대상자들에게 여주, 산수유, 오미자 그리고 대추의 혼합 추출물을 섭취시켰을 때 고지혈증 예방 및 개선 효과가 있다는 것을 혈중 총콜레스테롤, HDL-콜레스테롤 그리고 중성지방 농도 변화로 확인하였다. The results of the above experiment showed that when the mixed extracts of Yeoju, Sansui, Omija and Jujube were administered to the subjects in the pre-hyperlipidemia, the effect of preventing and improving hyperlipemia was evaluated as follows: total cholesterol, HDL-cholesterol and triglyceride .
혼합추출물을 섭취하는 기간이 증가할수록 총콜레스테롤과 중성지방의 농도는 낮아졌고, HDL-콜레스테롤은 상승하였다. 혼합추출물의 섭취에 의해 고지혈증 전단계 성인들은 고지혈증으로 진전되지 않고 정상인으로 회복되었다. 그리고 이런 효과는 고지혈증 개선 식사와 함께 혼합추출물을 섭취했을 때 더 뚜렷한 경향이 있었다. 따라서 일반식사와 함께 혼합추출물을 섭취하더라도 고지혈증을 예방 및 개선할 수 있지만 고지혈증 개선 식사와 함께 혼합추출물을 섭취한다면 더욱 효과적으로 고지혈증을 예방 및 개선할 수 있을 것으로 기대된다. The total cholesterol and triglyceride levels were lower and the HDL-cholesterol level increased as the period of intake of the mixed extract increased. Adults with pre - hyperlipidemia did not develop hyperlipidemia and recovered to normals by ingestion of mixed extracts. And this effect tended to be more pronounced when mixed extracts were supplemented with a hyperlipidemic diet. Therefore, it is expected that hyperlipidemia can be prevented and improved even if mixed extract is ingested together with regular meal.
이상, 본 발명은 일 실시 예를 참고로 설명되었으나 이는 예시적인 것에 불과하며, 당해 기술분야에서 통상의 지식을 가진 자라면 이로부터 다양한 변형 및 균등한 실시 예가 가능하다는 점을 이해할 것이다. 따라서 본 발명의 진정한 보호 범위는 첨부된 등록청구범위에 의해서만 정해져야 할 것이다.While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be clearly understood that the same is by way of illustration and example only and is not to be taken by way of limitation. Accordingly, the true scope of protection of the present invention should be determined only by the appended claims.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140012220A KR101533910B1 (en) | 2014-02-03 | 2014-02-03 | Composition for preventing and improving hyperlipidemia comprising extracts of Momordica charantia, Corni fructus, Schizandra chinensis and Jujube |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140012220A KR101533910B1 (en) | 2014-02-03 | 2014-02-03 | Composition for preventing and improving hyperlipidemia comprising extracts of Momordica charantia, Corni fructus, Schizandra chinensis and Jujube |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101533910B1 true KR101533910B1 (en) | 2015-07-06 |
Family
ID=53789149
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020140012220A KR101533910B1 (en) | 2014-02-03 | 2014-02-03 | Composition for preventing and improving hyperlipidemia comprising extracts of Momordica charantia, Corni fructus, Schizandra chinensis and Jujube |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101533910B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102001386B1 (en) | 2018-12-14 | 2019-07-18 | 주식회사 신우코퍼레이션 | Composition for anti-hyperlipidemia and antioxidant comprising red ginseng extract |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19990039366A (en) * | 1997-11-12 | 1999-06-05 | 박원훈 | Composition for inhibiting cholesterol lowering and cholesterol ester transfer protein containing jujube extract |
KR100862096B1 (en) * | 2007-04-06 | 2008-10-09 | 주식회사 글루칸 | An anti-diabetes composition comprising beta glucan and bitter melon extract as effective ingredients |
-
2014
- 2014-02-03 KR KR1020140012220A patent/KR101533910B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19990039366A (en) * | 1997-11-12 | 1999-06-05 | 박원훈 | Composition for inhibiting cholesterol lowering and cholesterol ester transfer protein containing jujube extract |
KR100862096B1 (en) * | 2007-04-06 | 2008-10-09 | 주식회사 글루칸 | An anti-diabetes composition comprising beta glucan and bitter melon extract as effective ingredients |
Non-Patent Citations (4)
Title |
---|
옥은성, 한국식품영양과학회지, 1995, 24(5), 658-662 * |
옥은성, 한국식품영양과학회지, 1995, 24(5), 658-662* |
최종연구보고서, "산수유를 이용한 기능성 가공식품 개발" (2003년) * |
최종연구보고서, "산수유를 이용한 기능성 가공식품 개발" (2003년)* |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102001386B1 (en) | 2018-12-14 | 2019-07-18 | 주식회사 신우코퍼레이션 | Composition for anti-hyperlipidemia and antioxidant comprising red ginseng extract |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5275251B2 (en) | Composition comprising an extract of a combined herb for preventing and treating liver disease | |
KR101464337B1 (en) | Composition for anti-obesity comprising extract of Diospyros lotus as effective component | |
JP2008297209A (en) | Lipid metabolism-improving composition | |
KR101523663B1 (en) | A composition for preventing or treating fatty liver disease or obesity, comprising a extract of Arctium lappa Linne, Glycyrrhiza uralensis Fischer, Zingiberis rhizoma Crudus and Magnoliae Cortex | |
JP2008214191A (en) | Agent for suppressing accumulation of lipid in liver | |
KR101536974B1 (en) | Composition for preventing and improving diabetes comprising extracts of Momordica charantia, Corni fructus, Schizandra chinensis and Jujube | |
KR102112599B1 (en) | Anti-obesity composition comprising Punica granatum and Citrus junos extract as effective component | |
KR101690369B1 (en) | Anti-obesity composition containing bitter melon mixture hot water extract and manufacturing method thereof | |
KR101533910B1 (en) | Composition for preventing and improving hyperlipidemia comprising extracts of Momordica charantia, Corni fructus, Schizandra chinensis and Jujube | |
KR20190053108A (en) | A composition comprising the complex extract for antiobesity of men | |
KR101692604B1 (en) | Composition comprising pomegranate juice extrated low speeed for improving liver function | |
KR102203657B1 (en) | A composition comprising the complex extract for antiobesity of women | |
KR101248378B1 (en) | Pharmaceutical composition for arthritis treatment and prevention | |
KR20180065419A (en) | Composition for anti-inflammation with nipa fruticans wurmb | |
KR100888068B1 (en) | Compositions for suppressing obesity | |
KR101154031B1 (en) | Composition for Antifati gue containin g herbal mixture extract as in gredient compounds | |
KR101662887B1 (en) | Composition Comprising Actinidia arguta shoot extract for prevention or treatment of nonalcoholic fatty liver disease | |
KR20150072659A (en) | Hepatoprotective composition containing smilax china extract | |
JP2005053786A (en) | Food and drink comprising extract derived from citrus pericarp and having inhibitory action on blood pressure rise | |
KR20130082249A (en) | Composition for preventing or improving the metabolic syndrome containing parthenocissus tricuspidata extract | |
KR101338532B1 (en) | Composition for preventing or treating colon cancer containing extract of sea cucumber | |
US11285188B2 (en) | Composition for preventing or treating metabolic diseases containing artemisiae capillaris herba and citrus unshiu peel complex extracts as active ingredients | |
KR102355441B1 (en) | Composition containing extract of Angelica gigas, extract of Cynanchum wilfordii and extract of Ginko biloba leaves for improving blood circulation | |
KR102183916B1 (en) | Composition containing complex extracts for preventing, improving or treating dyslipidemia | |
KR102464897B1 (en) | Herbal Compositions for Prevention, Improvement or Treatment of Benign Prostatic Hyperplasia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20180508 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20190514 Year of fee payment: 5 |